Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Hold On Seattle Genetics' Trials Clouds CD33's Suitability for AML

Executive Summary

FDA has placed clinical holds on several Phase I trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia after four patients died, clouding a field that is still in the shadow of Pfizer's failed Mylotarg.


Related Content

A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A
Cyclacel CEO Explains How Sapacitabine Might Get Cleared For AML, Despite Phase III Failure
AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces
AML Master Protocol For Precision Medicine Developed By Nonprofit And US FDA
Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts